Prevalence and Severity of Sarcopenia in Patients on Maintenance Hemodialysis: a Cross-sectional Study

Overview

Journal BMC Nephrol

Publisher Biomed Central

Specialty Nephrology

Date 2024 Oct 30

PMID 39472785

Authors

Yujie Yang

Ying Zeng

Wenmei Lv

Ping Fu

Huaihong Yuan

Affiliations

Soon will be listed here.

Abstract

Background: Sarcopenia, the progressive loss of muscle mass and strength, is common among patients with chronic kidney disease, especially those on maintenance hemodialysis. This condition often arises from factors like reduced physical activity and metabolic changes associated with chronic kidney disease. This study aims to assess the prevalence and severity of sarcopenia in patients on maintenance hemodialysis (MHD), focusing on probable sarcopenia and its correlations with physical activity, body mass index, and inorganic phosphorus levels.

Methods: This cross-sectional study involved 220 patients on MHD who visited to West China Hospital of Sichuan University between February and April 2023. The demographic data, body measurements, and laboratory results were retrospectively collected. Sarcopenia was assessed using the 2019 criteria from the Asian Working Group and the European Working Group on Sarcopenia in Older People, and physical activity was measured via the International Physical Activity Questionnaire.

Results: Of the study participants, 141 (64.1%) were diagnosed with probable [110 (50.0%) or confirmed sarcopenia [31 (14.1%)], including 22 (10%) with severe sarcopenia. Multivariable logistic regression analysis revealed that physical activity (International Physical Activity Questionnaire score, OR = 0.998, 95% CI: 0.998-0.999, P < 0.001), body mass index (OR = 0.868, 95% CI: 0.788-0.957, P = 0.004), and inorganic phosphorus levels (OR = 0.513, 95% CI: 0.270-0.975, P = 0.042) independently influenced the likelihood of sarcopenia. Within the sarcopenic group, physical activity and BMI significantly correlated with the condition's severity.

Conclusion: The prevalence of probable or confirmed sarcopenia in patients on MHD is significant. Factors such as physical activity, body mass index, and inorganic phosphorus levels are independently associated the presence and severity of sarcopenia in this population.

Trial Registration: Chinese Clinical Trial Registry (ChiCTR2100051111), registered on 2021-09-13.

Citing Articles

Sarcopenia in Chronic Kidney Disease: A Narrative Review from Pathophysiology to Therapeutic Approaches.

Tsai C, Wang P, Hsiung T, Fan Y, Wu J, Kan W Biomedicines. 2025; 13(2).

PMID: 40002765 PMC: 11852367. DOI: 10.3390/biomedicines13020352.

The role of lean body mass in predicting mortality in hemodialysis patients across different age groups.

Kim J, Yi J, Kim J, Kim K, Song J, Lee S Sci Rep. 2025; 15(1):2150.

PMID: 39819998 PMC: 11739422. DOI: 10.1038/s41598-025-85994-0.

References

Ikizler T, Pupim L, Brouillette J, Levenhagen D, Farmer K, Hakim R . Hemodialysis stimulates muscle and whole body protein loss and alters substrate oxidation. Am J Physiol Endocrinol Metab. 2001; 282(1):E107-16. DOI: 10.1152/ajpendo.2002.282.1.E107. View

Mori K, Nishide K, Okuno S, Shoji T, Emoto M, Tsuda A . Impact of diabetes on sarcopenia and mortality in patients undergoing hemodialysis. BMC Nephrol. 2019; 20(1):105. PMC: 6437886. DOI: 10.1186/s12882-019-1271-8. View

Kittiskulnam P, Chertow G, Carrero J, Delgado C, Kaysen G, Johansen K . Sarcopenia and its individual criteria are associated, in part, with mortality among patients on hemodialysis. Kidney Int. 2017; 92(1):238-247. PMC: 5483392. DOI: 10.1016/j.kint.2017.01.024. View

Cruz-Jentoft A, Bahat G, Bauer J, Boirie Y, Bruyere O, Cederholm T . Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2018; 48(1):16-31. PMC: 6322506. DOI: 10.1093/ageing/afy169. View

Ren H, Gong D, Jia F, Xu B, Liu Z . Sarcopenia in patients undergoing maintenance hemodialysis: incidence rate, risk factors and its effect on survival risk. Ren Fail. 2016; 38(3):364-71. DOI: 10.3109/0886022X.2015.1132173. View

Pecoits-Filho R, Okpechi I, Donner J, Harris D, Aljubori H, Bello A . Capturing and monitoring global differences in untreated and treated end-stage kidney disease, kidney replacement therapy modality, and outcomes. Kidney Int Suppl (2011). 2020; 10(1):e3-e9. PMC: 7031690. DOI: 10.1016/j.kisu.2019.11.001. View

Leong D, Teo K, Rangarajan S, Lopez-Jaramillo P, Avezum Jr A, Orlandini A . Prognostic value of grip strength: findings from the Prospective Urban Rural Epidemiology (PURE) study. Lancet. 2015; 386(9990):266-73. DOI: 10.1016/S0140-6736(14)62000-6. View

March D, Wilkinson T, Burnell T, Billany R, Jackson K, Baker L . The Effect of Non-Pharmacological and Pharmacological Interventions on Measures Associated with Sarcopenia in End-Stage Kidney Disease: A Systematic Review and Meta-Analysis. Nutrients. 2022; 14(9). PMC: 9101978. DOI: 10.3390/nu14091817. View

Bowden Davies K, Pickles S, Sprung V, Kemp G, Alam U, Moore D . Reduced physical activity in young and older adults: metabolic and musculoskeletal implications. Ther Adv Endocrinol Metab. 2019; 10:2042018819888824. PMC: 6878603. DOI: 10.1177/2042018819888824. View

10.

Lamarca F, Carrero J, Rodrigues J, Bigogno F, Fetter R, Avesani C . Prevalence of sarcopenia in elderly maintenance hemodialysis patients: the impact of different diagnostic criteria. J Nutr Health Aging. 2014; 18(7):710-7. DOI: 10.1007/s12603-014-0505-5. View

11.

Peterson S, Braunschweig C . Prevalence of Sarcopenia and Associated Outcomes in the Clinical Setting. Nutr Clin Pract. 2015; 31(1):40-8. DOI: 10.1177/0884533615622537. View

12.

Cornejo-Pareja I, Vegas-Aguilar I, Fernandez-Jimenez R, Garcia-Garcia C, Bellido-Guerrero D, Tinahones F . Phase angle and COVID-19: A systematic review with meta-analysis. Rev Endocr Metab Disord. 2023; 24(3):525-542. PMC: 10036242. DOI: 10.1007/s11154-023-09793-6. View

13.

Steffl M, Bohannon R, Sontakova L, Tufano J, Shiells K, Holmerova I . Relationship between sarcopenia and physical activity in older people: a systematic review and meta-analysis. Clin Interv Aging. 2017; 12:835-845. PMC: 5441519. DOI: 10.2147/CIA.S132940. View

14.

Chen L, Woo J, Assantachai P, Auyeung T, Chou M, Iijima K . Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment. J Am Med Dir Assoc. 2020; 21(3):300-307.e2. DOI: 10.1016/j.jamda.2019.12.012. View

15.

Marzetti E, Calvani R, Tosato M, Cesari M, Bari M, Cherubini A . Sarcopenia: an overview. Aging Clin Exp Res. 2017; 29(1):11-17. DOI: 10.1007/s40520-016-0704-5. View

16.

Sprague S, Lerma E, McCormmick D, Abraham M, Batlle D . Suppression of parathyroid hormone secretion in hemodialysis patients: comparison of paricalcitol with calcitriol. Am J Kidney Dis. 2001; 38(5 Suppl 5):S51-6. DOI: 10.1053/ajkd.2001.28110. View

17.

Ji W, Liu X, Zheng K, Yang H, Cui J, Li W . Correlation of phase angle with sarcopenia and its diagnostic value in elderly men with cancer. Nutrition. 2021; 84:111110. DOI: 10.1016/j.nut.2020.111110. View

18.

Xiang T, Fu P, Zhou L . Sarcopenia and osteosarcopenia among patients undergoing hemodialysis. Front Endocrinol (Lausanne). 2023; 14:1181139. PMC: 10230055. DOI: 10.3389/fendo.2023.1181139. View

19.

Himmelfarb J, Ikizler T . Hemodialysis. N Engl J Med. 2010; 363(19):1833-45. DOI: 10.1056/NEJMra0902710. View

20.

Lee W, Liu L, Peng L, Lin M, Chen L . Comparisons of sarcopenia defined by IWGS and EWGSOP criteria among older people: results from the I-Lan longitudinal aging study. J Am Med Dir Assoc. 2013; 14(7):528.e1-7. DOI: 10.1016/j.jamda.2013.03.019. View